Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company

Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company

Novartis Attacks Cholesterol With $9.7 Billion Takeover of The Medicines Company

GALWAY, IRELAND--December 2, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical major Novartis International AG (NYSE:NVS) (Basel, Switzerland) is betting big on heart drug prospect inclisiran with a 8.8 billion euro ($9.7 billion) takeover of The Medicines Company (NASDAQ: MDCO) (New Jersey).

Within this article: Details takeover, drugs involved, rivals and market opportunity

Subscribe Now!(All Fields Required)

Standard Membership - Free